Stay updated on Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial page.

Latest updates to the Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedAdded revision tag v3.5.0 and removed revision tag v3.4.3.SummaryDifference0.0%

- Check26 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. No visible content changes are indicated.SummaryDifference0.0%

- Check48 days agoChange DetectedAdded Gastric Cancer to the related topics section and included Genetic and Rare Diseases Information Center as a resources reference.SummaryDifference0.1%

- Check55 days agoChange DetectedSite updated to revision v3.4.2; a government funding/status notice previously shown (v3.4.1) has been removed.SummaryDifference0.3%

- Check62 days agoChange DetectedAdded a government funding lapse notice with updated operating status for the NIH Clinical Center and updated the site version from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check69 days agoChange DetectedUI and metadata text on the study page were updated: a 'Show glossary' option was added, and new labels such as 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0' were introduced. The older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.SummaryDifference0.2%

Stay in the know with updates to Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial page.